Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models

There is a clear unmet need for novel therapeutic agents for management of primary and secondary brain tumors. Novel therapeutic agents with excellent central nervous system (CNS) penetration and therapeutic activity are urgently needed. EDO-S101 is a novel alkylating and histone deacetylase inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Yushi, Li, Zhimin, Copland, John A., Mehrling, Thomas, Tun, Han W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021334/
https://www.ncbi.nlm.nih.gov/pubmed/29963268
http://dx.doi.org/10.18632/oncotarget.25588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021334/
https://www.ncbi.nlm.nih.gov/pubmed/29963268
http://dx.doi.org/10.18632/oncotarget.25588

Ejemplares similares